Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart
Primary Purpose
Hypertension, Left Ventricular Diastolic Dysfunction
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Nebivolol
Sponsored by
About this trial
This is an interventional treatment trial for Hypertension focused on measuring Hypertension, high blood pressure, stress echocardiogram, nebivolol, left ventricular diastolic dysfunction
Eligibility Criteria
Inclusion Criteria:
- History of mild (140-160 / 90-100) to moderate (160-200 / 100-120) hypertension
- LV diastolic dysfunction (>/= Grade1)
- LV ejection fraction >50%
- Indexed left atrial volume >/= 28 mL/m^2
- In sinus rhythm at the time of enrollment
- Willingness to return for the 6-month follow up investigations
Exclusion Criteria:
Presence or history of any of the following at baseline:
- History of mitral valve disease of greater than mild severity or prosthetic mitral valve, congenital heart disease or permanent pacemaker
- Calculated creatinine clearance <50 mL/min
- Terminal Illness with expected Survival of <1 year
- Previous Heart Transplant
- Individuals who are institutionalized
- Systolic BP>180 mm Hg or diastolic BP > 120 mm Hg
Medical treatment for elevated BP with:
- Calcium channel blocker (e.g. verapamil, nifedipine);
- Alpha blocker (e.g. prazosin);
- Alpha agonist (e.g. α-methyldopa, hydralazine, clonidine)
- Patient unwilling or unable to provide informed consent for study participation
- Pregnancy (current, or anticipated within the study period)
- Secondary Hypertension
- Previous echo contrast allergy
- Poor echocardiography window
- Previous stroke, known carotid stenosis
- Contraindication for beta-blocker therapy (sinus bradycardia <50 beats/min);
- 2nd or 3rd degree AV conduction block
- Overt congestive cardiac failure (NYHA Class III-IV)
- Known bronchospastic disease
- Known hepatic dysfunction (SGOT/PT > twice above normal levels)
Sites / Locations
- Icahn School of Medicine at Mount Sinai
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Nebivolol
Arm Description
Nebivolol 5 mg (titrated to a maximal dose of 10mg for optimal blood pressure) for 6 months
Outcomes
Primary Outcome Measures
Improvement in Exercise Tolerance
measured by stress echocardiogram, number of participants who had improvement in METS and improvement in exercise time as compared to their baseline.
Secondary Outcome Measures
E Velocity Indexed to e' (E/e' Ratio) of the Left Ventricle
measured as a part of stress echocardiogram, E/e' ratio: The normal E/e' ratio from the medial annulus is <8 and suggests a normal left atrial pressure. While values between 8 and 12 are indeterminate, a value >12 is indicative of an elevated left atrial pressure or PCWP (>18mmHg). The ranges for E/e' from the lateral mitral annulus are <5, 5 -10 and >10 respectively.
Untwist Rate of the Left Ventricle
measured as a part of stress echocardiogram, number of participants with significant improvement in the LV untwist after Nebivolol treatment in patients who completed the study
Full Information
NCT ID
NCT01961323
First Posted
October 9, 2013
Last Updated
October 19, 2017
Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
Forest Laboratories
1. Study Identification
Unique Protocol Identification Number
NCT01961323
Brief Title
Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart
Official Title
Effects of Nebivolol on Left Ventricular and Left Atrial Morphodynamics in Adults With Hypertension and Isolated Diastolic Dysfunction
Study Type
Interventional
2. Study Status
Record Verification Date
October 2017
Overall Recruitment Status
Completed
Study Start Date
March 2012 (undefined)
Primary Completion Date
March 2016 (Actual)
Study Completion Date
March 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
Forest Laboratories
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To investigate whether treatment with Nebivolol in subjects with high blood pressure and abnormal filling of left ventricle (LVDD) improves exercise time by improving Left Ventricular deformation and filling.
Detailed Description
Background:
The left ventricle (LV) ejects blood with a wringing motion, where the LV apex rotates counterclockwise and the base rotates in clockwise directions respectively. Rapid untwisting and recoil of LV during isovolumic relaxation and early diastole releases energy stored in ejection for LV suction and rapid early diastolic restoration. The LV geometry and its rotational mechanics also give rise to intracavitary blood flow rotation resulting into LV intracavitary vortex ring formation. LV torsion and vortex ring formation confer morphodynamic advantages that gain importance as blood flow velocities, heart rate and rates of change of momentum increase with exertion for improving LV efficiency. We have recently characterized the significance of LV twist mechanics and vortex ring formation in human hearts using novel high resolution speckle and contrast particle tracking echocardiography. Although data on a favorable effect of nebivolol on exercise capacity and LV diastolic filling exists, the changes in left ventricular (LV) rotational mechanics and blood flow vortex ring formation that may explain the potential hemodynamic benefits seen with nebivolol have not been previously characterized.
Aims:
In patients with hypertension and left ventricular diastolic dysfunction (LVDD) treatment with nebivolol for 6 months improves exercise time by enhancing:
LV deformation, torsion and untwisting mechanics
LA-to-LV blood flow transport and characteristics of intra-cavitary vortex formation
LA reservoir and booster pump function and LA-LV interaction during the conduit phase
Hypotheses:
Treatment with nebivolol in subjects with hypertension and LVDD improves exercise time by improving LV deformation and diastolic filling. As diastole shortens with the tachycardia associated with exercise, the contribution of untwist becomes relatively more important to LV suction and filling. Nebivolol improves LV diastolic filling primarily by enhancing LV untwisting and the rheological efficiency of blood flow transport through vortex formation in early diastole.
Significance:
Patients with LVDD are asymptomatic at rest and often but become markedly symptomatic with exertion. This pilot study will provide data for the first time for correlating the improvement in exercise capacity seen with the use of nebivolol with the changes in LV relaxation, torsional mechanics, LV vortex formation and LA-LV transport functions. The preliminary data will be essential for understanding the underlying pathophysiological mechanisms through which nebivolol improves exercise hemodynamics besides providing data for development of subsequent larger randomized multicentric trials.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Left Ventricular Diastolic Dysfunction
Keywords
Hypertension, high blood pressure, stress echocardiogram, nebivolol, left ventricular diastolic dysfunction
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
70 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Nebivolol
Arm Type
Experimental
Arm Description
Nebivolol 5 mg (titrated to a maximal dose of 10mg for optimal blood pressure) for 6 months
Intervention Type
Drug
Intervention Name(s)
Nebivolol
Intervention Description
Doses will be titrated based on weekly visits during the first 2 weeks to achieve a target SBP<140 and DBP <90 mm Hg. If BP remains uncontrolled after 2 weeks of treatment, indapamide will be added at a dosage of 2.5 mg/day. If the therapeutic goal is still not achieved by 4 weeks, patients will be withdrawn from the study.Upward titration will be halted, and the previous dosage level resumed, if at any point systolic blood pressure falls to ≤ 100 mmHg, even if the individual remains asymptomatic.
Primary Outcome Measure Information:
Title
Improvement in Exercise Tolerance
Description
measured by stress echocardiogram, number of participants who had improvement in METS and improvement in exercise time as compared to their baseline.
Time Frame
at 6 months
Secondary Outcome Measure Information:
Title
E Velocity Indexed to e' (E/e' Ratio) of the Left Ventricle
Description
measured as a part of stress echocardiogram, E/e' ratio: The normal E/e' ratio from the medial annulus is <8 and suggests a normal left atrial pressure. While values between 8 and 12 are indeterminate, a value >12 is indicative of an elevated left atrial pressure or PCWP (>18mmHg). The ranges for E/e' from the lateral mitral annulus are <5, 5 -10 and >10 respectively.
Time Frame
at 6 months
Title
Untwist Rate of the Left Ventricle
Description
measured as a part of stress echocardiogram, number of participants with significant improvement in the LV untwist after Nebivolol treatment in patients who completed the study
Time Frame
at 6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
History of mild (140-160 / 90-100) to moderate (160-200 / 100-120) hypertension
LV diastolic dysfunction (>/= Grade1)
LV ejection fraction >50%
Indexed left atrial volume >/= 28 mL/m^2
In sinus rhythm at the time of enrollment
Willingness to return for the 6-month follow up investigations
Exclusion Criteria:
Presence or history of any of the following at baseline:
History of mitral valve disease of greater than mild severity or prosthetic mitral valve, congenital heart disease or permanent pacemaker
Calculated creatinine clearance <50 mL/min
Terminal Illness with expected Survival of <1 year
Previous Heart Transplant
Individuals who are institutionalized
Systolic BP>180 mm Hg or diastolic BP > 120 mm Hg
Medical treatment for elevated BP with:
Calcium channel blocker (e.g. verapamil, nifedipine);
Alpha blocker (e.g. prazosin);
Alpha agonist (e.g. α-methyldopa, hydralazine, clonidine)
Patient unwilling or unable to provide informed consent for study participation
Pregnancy (current, or anticipated within the study period)
Secondary Hypertension
Previous echo contrast allergy
Poor echocardiography window
Previous stroke, known carotid stenosis
Contraindication for beta-blocker therapy (sinus bradycardia <50 beats/min);
2nd or 3rd degree AV conduction block
Overt congestive cardiac failure (NYHA Class III-IV)
Known bronchospastic disease
Known hepatic dysfunction (SGOT/PT > twice above normal levels)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Partho Sengupta, MD
Organizational Affiliation
Icahn School of Medicine at Mount Sinai
Official's Role
Principal Investigator
Facility Information:
Facility Name
Icahn School of Medicine at Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart
We'll reach out to this number within 24 hrs